ReachMD offentlig
[search 0]
Mer
Download the App!
show episodes
 
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.
  continue reading
 
Loading …
show series
 
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/integrating-bispecific-antibodies-into-clinical-practice/18063/ "Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatme…
  continue reading
 
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/considerations-for-dosing-bispecific-antibodies/18061/ "Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of hea…
  continue reading
 
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/bispecific-antibodies-the-newest-immunotherapy-on-the-block-for-rrmm/18055/ "Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for…
  continue reading
 
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/preventing-crs-and-neurotoxicities-related-to-bispecific-antibodies/18059/ "Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for …
  continue reading
 
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/step-up-dosing-of-bispecific-antibodies-the-need-for-hospitalization/18062/ "Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for…
  continue reading
 
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-evolving-treatment-paradigm-for-rrmm-the-role-of-bispecific-antibodies/18056/ "Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodi…
  continue reading
 
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/approved-bispecific-antibodies-for-rrmm-review-of-the-pivotal-trials/18057/ "Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for…
  continue reading
 
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/efficacy-data-for-bispecific-antibodies-in-rrmm/18058/ "Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of hea…
  continue reading
 
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/clinical-challenges-with-triple-class-or-penta-refractory-mm/18054/ "Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the tre…
  continue reading
 
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-infections-cytopenias-and-other-aes-related-to-bispecific-antibodies/18060/ "Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antib…
  continue reading
 
CME credits: 0.25 Valid until: 28-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/5-things-you-need-to-know-about-epilepsy-depression/16533/ A crucial aspect of epilepsy care that often goes underappreciated is the intersection of epilepsy and depression. Join Drs. Munger Clary and Salpekar, leading experts in the field, as they r…
  continue reading
 
CME credits: 0.50 Valid until: 28-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/unlocking-the-potential-of-her3-targeted-therapy-breakthroughs-in-egfr-mutant-nsclc-therapeutic-approaches/16214/ Dive into the forefront of precision oncology with Drs. Pasi Janne and Jyoti Patel, where they unravel the potential of HER3-directed an…
  continue reading
 
CME credits: 0.50 Valid until: 28-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/practical-management-of-variceal-bleeding-and-hepatorenal-syndrome/15771/ Extrahepatic manifestations of decompensated cirrhosis confer significant additional risks for mortality, and a multidisciplinary team of healthcare professionals is involved i…
  continue reading
 
CME credits: 0.25 Valid until: 28-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/unlocking-the-potential-of-her2-targeted-therapy-breakthroughs-in-nsclc-therapeutic-approaches/16213/ Dr. Helena Yu of Memorial Sloan Kettering Cancer Center presents an insightful overview of HER2 targeted therapy in non-small cell lung cancer (NSCL…
  continue reading
 
CME credits: 0.25 Valid until: 28-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/unlocking-the-potential-of-trop2-targeted-therapy-breakthroughs-in-nsclc-therapeutic-approaches/16212/ Drs. Benjamin Levy and Alex Spira discuss the emerging role of TROP2 as a therapeutic target in non-small cell lung cancer (NSCLC) on ReachMD. They…
  continue reading
 
CME credits: 1.00 Valid until: 27-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/improving-interprofessional-management-and-clinical-outcomes-with-parp-inhibitors-for-advanced-ovarian-cancer-parp-inhibitor-related-adverse-events-and-team-based-care/15665/ The establishment of poly (adenosine diphosphate [ADP]-ribose) polymerase (…
  continue reading
 
CME credits: 1.00 Valid until: 27-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/improving-interprofessional-management-and-clinical-outcomes-with-parp-inhibitors-for-advanced-ovarian-cancer-cytogenetic-testing-and-parp-inhibition-for-maintenance-treatment/15664/ The establishment of poly (adenosine diphosphate [ADP]-ribose) poly…
  continue reading
 
CME credits: 0.25 Valid until: 26-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/case-based-management-of-hyperkalemia-to-optimize-raasi-therapy-in-patients-with-ckd/16624/ Delve into refining the management of hyperkalemia in CKD patients and their associated comorbidities, striking a delicate balance that preserves guideline-re…
  continue reading
 
CME credits: 1.00 Valid until: 14-11-2024 Claim your CME credit at https://reachmd.com/programs/cme/improving-outcomes-in-patients-with-rvo-tailoring-treatment/16626/ Dr. Carl Danzig, Director of Vitreoretinal Services and Retina Clinical Research of Rand Eye Institute in Deerfield Beach, Florida, and Dr. Arshad Khanani, Clinical Associate Professo…
  continue reading
 
CME credits: 0.50 Valid until: 20-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/revolutionizing-care-for-patients-with-t2d-and-obesity-from-pathophysiology-to-personalized-treatments/16467/ Embark on a transformative journey to redefine patient care for individuals with type 2 diabetes by transitioning from the conventional focu…
  continue reading
 
CME credits: 0.25 Valid until: 12-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-to-common-questions-on-response-matters-transforming-the-standard-of-care-in-cml-by-mastering-response-guided-treatment/15663/ Chronic myeloid leukemia is a myeloproliferative neoplasm characterized by disordered growth of myeloid cell…
  continue reading
 
CME credits: 0.25 Valid until: 13-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-centric-approaches-to-managing-migraines-in-the-female-patient/16281/ Half of the women in the US with migraine are never diagnosed. Of those who are, the journey to effective treatment may last a decade or longer. But newer and more effectiv…
  continue reading
 
CME credits: 0.25 Valid until: 05-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-to-common-questions-for-tailoring-adc-therapies-across-the-her2-spectrum-in-metastatic-breast-cancer/15658/ HER2 is a well-established negative prognostic factor for metastatic breast cancer (mBC) and determining HER2 levels is essenti…
  continue reading
 
CME credits: 1.00 Valid until: 05-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-current-standard-for-first-line-treatment-of-metastatic-her2-positive-ggej-cancers/18026/ The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selectio…
  continue reading
 
CME credits: 1.00 Valid until: 05-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-evidence-supporting-cldn182-targeting-in-frontline-management-of-ggej-cancers/18027/ The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Re…
  continue reading
 
CME credits: 1.00 Valid until: 05-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/incorporating-data-into-practice-late-breaking-highlights-on-ggej-cancers-from-the-2024-gi-congress/18028/ The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment sel…
  continue reading
 
CME credits: 1.00 Valid until: 05-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/her2-pd-l1-exploring-clinical-characteristics-of-ggej-cancers-in-relation-to-biomarker-positivity/18023/ The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selec…
  continue reading
 
Loading …

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett